Pharsight

NOVARTIS PHARMA AG patents facing oppositions

Top patents of NOVARTIS PHARMA AG facing oppositions at the European Patent Office (EPO).

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP3351246B8 18 Sep, 2019 Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis Feb, 2022 10
EP3342411B1 21 Aug, 2019 Rapamycin derivative for treating pancreas cancer Feb, 2022 10
EP2784084B2 04 Oct, 2023 Antagonist antibodies to IL-17A/F heterologous polypeptides Jun, 2024 4
EP3345602B1 06 Apr, 2022 Rapamycin derivative for treating solid tumours Feb, 2022 3